이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

STRATA Skin Sciences 배당금

배당금 기준 확인 0/6

STRATA Skin Sciences 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$3.24
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

Jun 07

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

Mar 19

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Dec 31

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Nov 03

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

Jul 04

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Apr 18

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Jan 14

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

Aug 10

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

Jul 25

What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 09

Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years

Nov 24

STRATA Skin Sciences EPS in-line, beats on revenue

Nov 10

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 SSKN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: SSKN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

STRATA Skin Sciences 시장 대비 배당 수익률

SSKN 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (SSKN)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.8%
업계 평균 (Medical Equipment)	1.8%
3년 후 애널리스트 예측 (SSKN)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SSKN 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SSKN 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SSKN 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: SSKN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

STRATA Skin Sciences 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

STRATA Skin Sciences Regains Compliance with Nasdaq Rule 5550(a)(2)

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

Consensus EPS estimates fall by 33%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

STRATA Skin Sciences, Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 15%

No longer forecast to breakeven

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

STRATA Skin Sciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Strata Skin Sciences, Inc. Promotes Shmuel Gov to the Position of Chief Operating Officer

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 11% to US$3.60

STRATA Skin Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Less than half of directors are independent

STRATA Skin Sciences, Inc. Announces Management Change

STRATA Skin Sciences, Inc., Annual General Meeting, Oct 26, 2023

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Forecast breakeven date moved forward to 2024

STRATA Skin Sciences, Inc. to Report Q2, 2023 Results on Aug 09, 2023

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

STRATA Skin Sciences, Inc. Announces Board Changes

STRATA Skin Sciences, Inc. Announces First Patients Treated in TheraClear®X Clinical Study for Acne

First quarter 2023 earnings: EPS misses analyst expectations

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

STRATA Skin Sciences Announces TheraClearX Product Demonstration at Inaugural Winter Clinical Conference

STRATA Skin Sciences, Inc. Revises Revenue Guidance for the Full Year 2022

STRATA Skin Sciences, Inc. Announces Poster Accepted at ODAC Dermatology, Aesthetic & Surgical Conference

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Consensus estimates of losses per share improve by 12%

Forecast to breakeven in 2024

STRATA Skin Sciences, Inc. Reiterates Earnings Guidance for the Year 2022

STRATA Skin Sciences Receives Non-Compliance Letter from NASDAQ

STRATA Skin Sciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

STRATA Skin Sciences, Inc. Provides Revenue Guidance Full Year 2022

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

STRATA Skin Sciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Strata Skin Sciences Announces U.S. Commercial Launch of Theraclear®X Acne Therapy System

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

STRATA Skin Sciences, Inc., Annual General Meeting, Jun 22, 2022

Consensus forecasts updated

STRATA Skin Sciences, Inc. Names Michael E. Goodman as Head of International Sales

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

STRATA Skin Sciences, Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$4.30

STRATA Skin Sciences, Inc. Appoints Patricia S. Walker to Its Board of Director

STRATA Skin Sciences Announces Commercial Launch of XTRAC Momentum 1.0 and First Installation in the U.S

STRATA Skin Sciences, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2021

Third quarter 2021 earnings released: US$0.015 loss per share (vs US$0.037 loss in 3Q 2020)

Price target increased to US$4.80

Independent Director recently bought US$104k worth of stock

Second quarter 2021 earnings released: EPS US$0.032 (vs US$0.05 loss in 2Q 2020)

STRATA Skin Sciences, Inc. (NasdaqCM:SSKN) entered into a definitive agreement to acquire U.S. Dermatology Business of Ra Medical Systems, Inc. from Ra Medical Systems, Inc. (NYSEAM:RMED) for $3.7 million.

Price target increased to US$4.20

Independent Director Samuel Navarro has left the company

Consensus EPS estimates fall to -US$0.17

First quarter 2021 earnings released: US$0.072 loss per share (vs US$0.031 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.11 loss in FY 2019)

Strata Skin Sciences Announces Expanded Distribution Agreement in China with Wuhan Miracle Laser Systems, Inc

What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

STRATA Skin Sciences, Inc. Announces Executive Changes

CEO, President & Director Dolev Rafaeli has left the company

STRATA Skin Sciences, Inc. to Report Q4, 2020 Results on Mar 24, 2021

New 90-day high: US$2.16

New 90-day high: US$2.08

STRATA Skin Sciences Announces the Introduction of Home by XTRAC™